Clinical bottom line
Pancreatic alpha cell dysfunction and glucagon dysregulation contribute significantly to the pathophysiology of both type 1 and type 2 diabetes, influencing glycemic instability and disease progression. Emerging therapies targeting alpha cell plasticity and restoring key signaling pathways, such as glutamate receptor signaling, show promise in normalizing glucagon secretion and improving metabolic control. While preclinical and early clinical data are encouraging, these approaches remain investigational and warrant further validation before routine clinical application.
What the evidence shows
Alpha cells, which secrete glucagon, play a critical counterregulatory role in glucose homeostasis. Dysregulation of alpha cell function contributes to both hyperglucagonemia in type 2 diabetes and impaired glucagon responses in type 1 diabetes, exacerbating glycemic variability (Winson et al., 2024; Subramanian et al., 2025). Recent studies have highlighted the plasticity of alpha cells, including their ability to alter hormone secretion profiles and receptor expression in response to metabolic stress.
A key mechanistic insight involves glutamate receptor signaling within alpha cells. Panzer et al. (2022) demonstrated that restoring glutamate receptor function in pancreatic alpha cells rescued defective glucagon secretion in type 1 diabetes models, suggesting a novel therapeutic target. This work builds on earlier findings that alpha cell autoantibodies correlate with impaired glucagon responses (Winter et al., 1984), indicating immune-mediated alpha cell dysfunction.
Mathematical modeling studies further support the concept that alpha cell dysregulation contributes to the progression from insulin resistance to overt type 2 diabetes by disrupting the balance between insulin and glucagon secretion (Subramanian et al., 2025). Emerging glucagon-based therapies, including agents modulating alpha cell signaling pathways and glucagon receptor activity, are under investigation to restore this balance and improve glycemic control (Winson et al., 2024).
Although incretin-based therapies primarily target beta cells and insulin secretion, their effects on alpha cells and glucagon secretion are increasingly recognized, adding complexity to therapeutic strategies (Garber et al., 2008).
Caveats and uncertainty
Current evidence is largely preclinical or early-phase clinical, with limited large-scale trials directly assessing alpha cell-targeted therapies in humans. The heterogeneity of alpha cell dysfunction across diabetes types and stages complicates generalization. Immune-mediated alpha cell damage in type 1 diabetes may require different therapeutic approaches compared to metabolic dysregulation in type 2 diabetes.
The long-term safety and efficacy of modulating alpha cell plasticity remain unknown. Potential off-target effects and the impact on overall islet cell function require careful evaluation. Additionally, the interplay between alpha cells and other islet cell types, including beta and delta cells, introduces complexity that current models may not fully capture.
How this may change practice
If validated in clinical trials, therapies targeting alpha cell plasticity and glucagon signaling could complement existing diabetes treatments by addressing a key but underappreciated pathophysiological mechanism. This may improve glycemic stability, reduce hypoglycemia risk, and slow disease progression.
Clinicians should remain aware of ongoing developments in this area, as future treatment paradigms may incorporate agents that specifically restore alpha cell function or modulate glucagon secretion. Integration with current therapies, including insulin and incretin-based agents, will require careful clinical evaluation.
In the near term, understanding alpha cell dysfunction may enhance clinicians’ interpretation of glycemic patterns and inform individualized treatment adjustments, particularly in patients with labile glucose control or hypoglycemia unawareness.